RBM (Rules-Based Medicine) bags German cell culture test company:
This article was originally published in Clinica
Biomarker testing services provider Rules-Based Medicine (RBM) has bought human cell culture test systems firm Experimentelle and Diagnostische Immunologie (EDI) for an undisclosed fee. The two companies will collaborate to combine their technologies and develop biomarker test platforms - EDI's human organotypic (HOT) cell culture test systems complements RBM's Multi-Analyte Profiling (MAP) biomarkers for proteins, metabolites and other substances in the human blood. According to Austin, Texas-based RBM, the collaboration will help to standardise sample collection, cell treatment and result generation, and will make therapeutic and consumer product development more reliable and reproducible. EDI will become a subsidiary of RBM but will retain its operating facilities in Reutlingen, Germany.